Drug-Eluting Balloon Treatment vs. Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques

NANot yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2033

Conditions
Coronary Artery DiseaseAtherosclerosesCardiovascular DiseaseVulnerable Coronary PlaquesVulnerable PlaqueLipid-Rich Atherosclerosis of Coronary ArteryAcute Coronary Syndromes (ACS)
Interventions
DEVICE

Paclitaxel-eluting balloon

Participants in the intervention group will receive local treatment of non-obstructive, lipid-rich coronary plaques using a paclitaxel-coated drug-eluting balloon (DCB) in addition to guideline-directed medical therapy (GDMT). The DCB will be applied to plaques identified as high-risk based on near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) imaging, defined by a maxLCBI4mm ≥325. The balloon catheter diameter will be sized 1:1 according to the true lumen diameter as derived from IVUS. Balloon length will be sized to the LRP length as measured with IVUS including a 5 mm margin on each side. The balloon will be inflated at nominal pressure (6-8 ATM) during a period of at least 60 seconds, but preferably for 90 seconds if tolerated. A 5 mm margin is taken into account to differentiate between single or multiple LRPs within the same coronary artery.

Trial Locations (1)

Unknown

Amsterdam UMC, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER